News | December 26, 2007

Canada Reactor Back in Business

December 27, 2007 - After a longer-than-expected maintenance shutdown, production of radioisotopes for molecular imaging and targeted therapy is back online at the National Research Universal (NRU) reactor in Chalk River, Ontario. The reactor was returned to service following direct intervention by the Canadian government, which in effect over-ruled the safety concerns of the Canadian Nuclear Safety Commission (CNSC).

The NRU entered a regularly scheduled maintenance shutdown on Nov. 18 (see A break in the supply chain on medicalphysicsweb). That shutdown resulted in an interruption in the supply of molybdenum-99 (Mo-99), a fission by-product that's used to make technetium-99m (Tc-99m) and iodine-131 (I-131). Tc-99m and I-131 are the predominant radionuclides used in diagnostic and therapeutic nuclear-medicine studies.

In early December, however, things started to get messy. Atomic Energy of Canada Limited (AECL), the government-owned company which runs the NRU reactor, announced an extension of the outage till early/mid-January to allow "modifications required for the installation of two new motor starters for the reactor cooling pump, and to connect the motors to an additional back-up power supply".

That announcement came against an already grim clinical backdrop, with thousands of seriously ill patients in North America facing delays to diagnostic procedures as a result of the disruption to isotope supply lines.

On Dec. 11, in response to concerns from the medical community, the Canadian parliament agreed a bill that temporarily suspended (for 120 days) the CNSC's oversight role, thus allowing the NRU to start up again even though it still did not fully meet safety standards.

The reactor was safely returned to service on Dec.16, which means that medical isotopes will by now be ready for removal, processing and distribution. In the coming weeks, AECL will complete the maintenance work during normal reactor operations.

The next time the NRU needs to be shut down for maintenance the AECL is likely to be better prepared. The agency has built two new reactors, MAPLE 1 and MAPLE 2, for exclusive production of medical isotopes. Originally scheduled to go online in 2004, they are now due to start up in October 2008 and October 2009, respectively.

• MDS Nordion (Ottawa, Canada), a leading supplier of medical isotopes, had reckoned it would take an $8-9 million earnings hit in its current quarter as a result of the NRU outage. With the reactor back online, however, the company anticipates less of a financial impact than previously estimated.

Source: Joe McEntee is editor of medicalphysicsweb. Additional reporting by physicsworld.com.

For more information: www.aecl.ca

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Contrast Media | August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Contrast Media from Bayer, trends in contrast media and developments in contrast media
Feature | Contrast Media | July 28, 2017 | By Dave Fornell
Here are several updates in medical imaging ...
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
July 18, 2017 — Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabri
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
FDA says gadolinium retention in the brain is not a safety issue
Feature | Magnetic Resonance Imaging (MRI) | May 25, 2017
A U.S. Food and Drug Administration (FDA) review of the safety ramifications of gadolinium-based contrast agents for...
Targeted MRI Could Pinpoint Aggressive Prostate Cancers Before They Spread

The ZD2-Gd probe, represented by the orange ball and green arrow, binds to the EDB-FN in the prostate cancer cells with high metastatic potential. This results in a strong MRI signal (upper right). Prostate cancer cells with low metastatic potential have no EDB-FN and so there is no MRI signal (lower right). Credit: Han, et al., Bioconjug Chem-Apr-2017

News | Prostate Cancer | May 24, 2017
A research team funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) has engineered a...
Scientists Develop Novel Chemical Dye to Improve MRI Liver Cancer Imaging
News | Magnetic Resonance Imaging (MRI) | May 03, 2017
May 3, 2017 — Scientists from the National University of Singapore (NUS) have developed a novel nanodiamond-based ...
Sponsored Content | Case Study | Contrast Media Injectors | April 13, 2017
The volume of computed tomography (CT) imaging exams continues to grow in the United States,[2] adding pressure to...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Overlay Init